Mercado and IAVI developed the COVID-19 vaccine, and the technology platform recombinant hydrocephalitis virus (rVSV) has successfully developed the Ebola vaccine Ervebo!

May 26, 2020 /
PRNewswire
BIOON/ -- Merck and Co has jointly announced a new partnership with the InternationalAIDS VaccineAction Organization (IAVI) to develop a vaccine product for the new coronavirus (SARS-CoV-2) for the prevention of new coronavirus pneumonia (COVID-19)this candidate vaccine will use recombinant ostosis virus (rVSV), which is the basis for the Ervebo (rVSV G-ZEBOV-GP, V920, detoxifying live vaccine) in MersadonErvebo was first in the European Union in November 2019 to be actively immunized for people aged 18 and over to prevent Ebola virus disease (EVD) caused by Ebola ZaireThe approval marks a historic milestone in making Ervebo the world's first regulatoryly approved Ebola vaccineCurrently, Ervebo has been approved in several countries in the United States and AfricaErvebo was the first to approve the rVSV vaccine for humansUnder the cooperation agreement, Mercadon and IAVI will work together to promote the development of IAVI scientists' design and engineering SARS-CoV-2 candidate vaccines and global clinical evaluationThe vaccine candidate is being developed in preclinical conditions and clinical studies are scheduled to begin later in 2020Mercado will lead the submission of regulatory documents worldwideIf approved, the two organizations will work together to develop vaccines that are readily available and affordable on a global scalePreclinical development of the rVSV vaccineIAVI, including the SARS-CoV-2 candidate vaccine, is being done by scientists at the IAVI Design and Development Laboratory (DDL) in Brooklyn, New YorkThe project is part of a long-term effort to develop rVSV vaccines for HIV and other emerging infectious diseases such as Lassa fever, Marburg and Ebola Sudan disease under the leadership of Dr Swati Gupta, IAVI's Director of Emerging Infectious Diseases and Scientific Strategy recombinant ostosis virus (rVSV) vaccine platform uses a reduced strain of the blister osmatitis virus (VSV), a common animal virus that has been modified to express proteins that stimulate the immune response IAVI and Mercadon will draw on the experience gained from the platform in developing the rVSV vaccine against the Ebola Zaire virus "COVID-19 is a huge scientific, medical and global health challenge," said Dr Roger M Perlmutter, President of the 's Mercado Research Laboratory Mercadon is working with organizations around the world to develop anti-infective drugs and vaccines to alleviate the pain caused by SARS-CoV-2 infection Both Mercado and IAVI are eager to combine their respective strengths to accelerate the development of a candidate vaccine for the rVSV vaccine in order to slow the coVID-19 epidemic "
IAVI President and CEO, Dr Mark Feinberg, said ", "We believe that the rVSV-based vaccine strategy is a promising way to help combat the new coronavirus pandemic." We look forward to working with Mercado to implement an accelerated development program to assess the potential of our SARS-CoV-2 candidate vaccine The partnership between Mercado and IAVI represents an innovative partnership model and approach to harnessing our combined capabilities in a complementary and collaborative manner to address this difficult global health challenge (biovalleybioon.com) original origin: IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2